Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.51 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.48 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.46 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.46 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13975682 | 1.00 | LMNA (0.56) | LMNAP2RX3P2RX4P2RX2PRMT6 | |
| SCHEMBL9850107 | 1.00 | LMNA (0.56) | LMNAP2RX3P2RX4P2RX2PRMT6 | |
| SCHEMBL21245357 | 0.93 | LMNA (0.58) | LMNAP2RX3P2RX4P2RX2PRMT6 | |
| SCHEMBL22983997 | 0.93 | P2RX3 (0.59) | LMNAP2RX3P2RX4P2RX2PRMT6 | |
| SCHEMBL21750474 | 0.92 | PRMT6 (0.50) | LMNAP2RX3P2RX4P2RX2PRMT6 | |
| SCHEMBL21750476 | 0.92 | PRMT6 (0.50) | LMNAP2RX3P2RX4P2RX2PRMT6 | |
| SCHEMBL13396711 | 0.92 | PRMT6 (0.50) | LMNAP2RX3P2RX4P2RX2PRMT6 | |
| SCHEMBL13396713 | 0.91 | PRMT6 (0.51) | LMNAP2RX3P2RX4P2RX2PRMT6 | |
| SCHEMBL30019683 | 0.89 | LMNA (0.48) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL23169729 | 0.89 | LMNA (0.57) | LMNAPRMT6P2RY12P2RY2P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196419-B2 | Processes and intermediates for preparing anti-HIV agents | GILEAD SCIENCES, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180079773-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. | 2018-03-22 | — | — | US | disclosed |
| US-9783567-B2 | Processes and intermediates for preparing anti-HIV agents | GILEAD SCIENCES, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-3199537-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2710019-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160340379-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9296779-B2 | Processes and intermediates for preparing anti-HIV agents | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150203525-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-8987437-B2 | Processes and intermediates for preparing anti-HIV Agents | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-0428109-A2 | Deoxyfluoronucleoside process | Bristol-Myers Squibb Company (US) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196419-B2 | Processes and intermediates for preparing anti-HIV agents | SAMHD1, DHPS, LSS | LMNA 1511/4885P2RX3 3971/4885P2RX4 3392/4885 |
| US-20150203525-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | SAMHD1, DHPS, LSS | LMNA 1511/4885P2RX3 3971/4885P2RX4 3392/4885 |
| US-20160340379-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | SAMHD1, DHPS, LSS | LMNA 1511/4885P2RX3 3971/4885P2RX4 3392/4885 |
| US-20180079773-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | SAMHD1, DHPS, LSS | LMNA 1511/4885P2RX3 3971/4885P2RX4 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.